Douglas Fambrough, Dicerna CEO (Boehringer Ingelheim via YouTube)

Roche-backed Dicer­na push­es in­to the pack rac­ing to­ward the block­buster hep B goal line, armed with PhI da­ta

Dicer­na has lined up a set of proof-of-con­cept da­ta from a small co­hort of he­pati­tis B pa­tients in a match-up against some heavy­weight ri­vals which got out in front of this race. And right in the front row you’ll find a team from Roche, which paid $200 mil­lion in cash and of­fered an­oth­er $1.5 bil­lion in mile­stones to part­ner with Dicer­na $DR­NA on their RNAi pro­gram for hep B.

Right now it’s look­ing com­pet­i­tive, with lots of big chal­lenges ahead.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.